Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Apr 2026
Nearly 400 trials and Belgium’s isotope hub signal rapid clinical diversification for radioligand therapy — but policy, funding, and system readiness must follow.
Read Full NewsForget salary. The cities winning the physician satisfaction race are playing a completely different game.
The prevalence of type 2 diabetes is rising among US youth, and if we don’t address the real causes, we really will see a potentially unstoppable surge.
Current evidence supports the use of this botanical agent to promote skin health, but more research is needed to ascertain more varied and curative applications for this popular natural product.
CRISPR cures for sickle cell disease, gene therapy for hemophilia A, and expanding CAR T cell uses point to a new era of potentially curative, personalized treatments.
Dr Teresa Amaral reviews new uveal melanoma guidelines, focusing on AJCC 8th Edition staging, the Liverpool prognostic tool, and the essential role of BAP1 and PRAME expression.
The Red Cross on Saturday paid tribute to three volunteers who are believed to have died after contracting Ebola while handling bodies.
Americans coming back from the Democratic Republic of the Congo, Uganda or South Sudan now have a second entry point for returning to the United States, with the CDC on...
1.
Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.
2.
Obesity-related cancers are more likely in people who are obese in both healthy and unhealthy ways.
3.
Promising for Monitoring and Diagnosis of AD is the finger-prick test.
4.
Men over 75 years old may be significantly more likely to commit suicide if they have cancer.
5.
In prostate cancer survivorship, sleep disturbances are underappreciated.
1.
The Potential of Amifostine in Cancer Treatment: A Revolutionary Breakthrough
2.
Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development
3.
Survival Rate Dynamics in Hematologic and Solid Malignancies
4.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
5.
Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
Navigating the Complexities of Ph Negative ALL - Part VII
5.
Navigating the Complexities of Ph Negative ALL - Part XVI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge